213 related articles for article (PubMed ID: 35796022)
1. Regulation of temozolomide resistance via lncRNAs: Clinical and biological properties of lncRNAs in gliomas (Review).
Li S; Xie X; Peng F; Du J; Peng C
Int J Oncol; 2022 Sep; 61(3):. PubMed ID: 35796022
[TBL] [Abstract][Full Text] [Related]
2. [Systemic treatment of adult gliomas: a narrative review].
Mangel L
Magy Onkol; 2024 Mar; 68(1):67-75. PubMed ID: 38484377
[TBL] [Abstract][Full Text] [Related]
3. Temozolomide Resistance in Glioblastoma by NRF2: Protecting the Evil.
Almeida Lima K; Osawa IYA; Ramalho MCC; de Souza I; Guedes CB; Souza Filho CHD; Monteiro LKS; Latancia MT; Rocha CRR
Biomedicines; 2023 Apr; 11(4):. PubMed ID: 37189700
[TBL] [Abstract][Full Text] [Related]
4. Protein degradation: expanding the toolbox to restrain cancer drug resistance.
Ming H; Li B; Jiang J; Qin S; Nice EC; He W; Lang T; Huang C
J Hematol Oncol; 2023 Jan; 16(1):6. PubMed ID: 36694209
[TBL] [Abstract][Full Text] [Related]
5. Activated TRPA1 plays a therapeutic role in TMZ resistance in glioblastoma by altering mitochondrial dynamics.
Chen H; Li C; Hu H; Zhang B
BMC Mol Cell Biol; 2022 Aug; 23(1):38. PubMed ID: 35982414
[TBL] [Abstract][Full Text] [Related]
6. Decoding key cell sub-populations and molecular alterations in glioblastoma at recurrence by single-cell analysis.
Wang X; Sun Q; Wang W; Liu B; Gu Y; Chen L
Acta Neuropathol Commun; 2023 Jul; 11(1):125. PubMed ID: 37525259
[TBL] [Abstract][Full Text] [Related]
7. IRP1 mediated ferroptosis reverses temozolomide resistance in glioblastoma via affecting LCN2/FPN1 signaling axis depended on NFKB2.
Lan Y; Yang T; Yue Q; Wang Z; Zhong X; Luo X; Zuo B; Zhang M; Zeng T; Liu B; Guo H
iScience; 2023 Aug; 26(8):107377. PubMed ID: 37520713
[TBL] [Abstract][Full Text] [Related]
8. Circ
Li J; Ma J; Huang S; Li J; Zhou L; Sun J; Chen L
Mol Cell Biol; 2023; 43(7):354-369. PubMed ID: 37427890
[TBL] [Abstract][Full Text] [Related]
9. Deciphering glioma epitranscriptome: focus on RNA modifications.
Piperi C; Markouli M; Gargalionis AN; Papavassiliou KA; Papavassiliou AG
Oncogene; 2023 Jul; 42(28):2197-2206. PubMed ID: 37322070
[TBL] [Abstract][Full Text] [Related]
10. Pyroptosis, ferroptosis, and autophagy cross-talk in glioblastoma opens up new avenues for glioblastoma treatment.
Wan S; Zhang G; Liu R; Abbas MN; Cui H
Cell Commun Signal; 2023 May; 21(1):115. PubMed ID: 37208730
[TBL] [Abstract][Full Text] [Related]
11. CD147 and cyclophilin A: a promising potential targeted therapy for COVID-19 and associated cancer progression and chemo-resistance.
Bakhtiyari M; Haji Aghasi A; Banihashemi S; Abbassioun A; Tavakol C; Zalpoor H
Infect Agent Cancer; 2023 Apr; 18(1):20. PubMed ID: 37016434
[TBL] [Abstract][Full Text] [Related]
12. TFR2 regulates ferroptosis and enhances temozolomide chemo-sensitization in gliomas.
Tong S; Hong Y; Xu Y; Sun Q; Ye L; Cai J; Ye Z; Chen Q; Tian D
Exp Cell Res; 2023 Mar; 424(1):113474. PubMed ID: 36702193
[TBL] [Abstract][Full Text] [Related]
13. PDIA3P1 promotes Temozolomide resistance in glioblastoma by inhibiting C/EBPβ degradation to facilitate proneural-to-mesenchymal transition.
Gao Z; Xu J; Fan Y; Qi Y; Wang S; Zhao S; Guo X; Xue H; Deng L; Zhao R; Sun C; Zhang P; Li G
J Exp Clin Cancer Res; 2022 Jul; 41(1):223. PubMed ID: 35836243
[TBL] [Abstract][Full Text] [Related]
14. High levels of NRF2 sensitize temozolomide-resistant glioblastoma cells to ferroptosis via ABCC1/MRP1 upregulation.
de Souza I; Monteiro LKS; Guedes CB; Silva MM; Andrade-Tomaz M; Contieri B; Latancia MT; Mendes D; Porchia BFMM; Lazarini M; Gomes LR; Rocha CRR
Cell Death Dis; 2022 Jul; 13(7):591. PubMed ID: 35803910
[TBL] [Abstract][Full Text] [Related]
15. Virus-Based Biological Systems as Next-Generation Carriers for the Therapy of Central Nervous System Diseases.
Nowak I; Madej M; Secemska J; Sarna R; Strzalka-Mrozik B
Pharmaceutics; 2023 Jul; 15(7):. PubMed ID: 37514117
[TBL] [Abstract][Full Text] [Related]
16. Insights into Healthcare Professionals' Perceptions and Attitudes toward Nanotechnological Device Application: What Is the Current Situation in Glioblastoma Research?
Ragucci F; Sireci F; Cavallieri F; Rossi J; Biagini G; Tosi G; Lucchi C; Molina-Pena R; Ferreira NH; Zarur M; Ferreiros A; Bourgeois W; Berger F; Abal M; Rousseau A; Boury F; Alvarez-Lorenzo C; Garcion E; Pisanello A; Pavesi G; Iaccarino C; Ghirotto L; Bassi MC; Valzania F
Biomedicines; 2023 Jun; 11(7):. PubMed ID: 37509494
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapy Approaches in Isocitrate-Dehydrogenase-Mutant Low-Grade Glioma.
Gallus M; Kwok D; Lakshmanachetty S; Yamamichi A; Okada H
Cancers (Basel); 2023 Jul; 15(14):. PubMed ID: 37509387
[TBL] [Abstract][Full Text] [Related]
18. The Glioma Immune Landscape: A Double-Edged Sword for Treatment Regimens.
Mahajan S; Schmidt MHH; Schumann U
Cancers (Basel); 2023 Mar; 15(7):. PubMed ID: 37046685
[TBL] [Abstract][Full Text] [Related]
19. Ferroptosis-related NFE2L2 and NOX4 Genes are Potential Risk Prognostic Biomarkers and Correlated with Immunogenic Features in Glioma.
Lin L; Li X; Zhu S; Long Q; Hu Y; Zhang L; Liu Z; Li B; Li X
Cell Biochem Biophys; 2023 Mar; 81(1):7-17. PubMed ID: 36627482
[TBL] [Abstract][Full Text] [Related]
20. Iron Oxide Nanoparticles Decorated with Functional Peptides for a Targeted siRNA Delivery to Glioma Cells.
Chung S; Sugimoto Y; Huang J; Zhang M
ACS Appl Mater Interfaces; 2023 Jan; 15(1):106-119. PubMed ID: 36442077
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
